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Literature studying the door-to-balloon time-outcome relation in coronary intervention is limited by the 
potential of residual biases from unobserved confounders. This study re-examines the time-outcome 
relation with further consideration of the unobserved factors and reports the population average effect. 
Adults with ST-elevation myocardial infarction admitted to one of the six registry participating hospitals 
in Australia were included in this study. The exposure variable was patient-level door-to-balloon time. 
Primary outcomes assessed included in-hospital and 30 days mortality. 4343 patients fulfilled the study 
criteria. 38.0% (1651) experienced a door-to-balloon delay of >90 minutes. The absolute risk differences 
for in-hospital and 30-day deaths between the two exposure subgroups with balanced covariates were 
2.81 (95% CI 1.04, 4.58) and 3.37 (95% CI 1.49, 5.26) per 100 population. When unmeasured factors 
were taken into consideration, the risk difference were 20.7 (95% CI −2.6, 44.0) and 22.6 (95% CI −1.7, 
47.0) per 100 population. Despite further adjustment of the observed and unobserved factors, this 
study suggests a directionally consistent linkage between longer door-to-balloon delay and higher risk 
of adverse outcomes at the population level. Greater uncertainties were observed when unmeasured 
factors were taken into consideration.
Door-to-balloon (D2B) time is an in-hospital process indicator of reperfusion timeliness in primary percutane-
ous coronary intervention (pPCI)1. The emphasis of achieving shorter D2B times in pPCI is based on the theo-
retical deduction of improved myocardial salvage with shorter ischemia-reperfusion interval. Backed by a body 
of real-world observational evidence, this idea had spurred a widespread focus of D2B time improvement across 
geographical regions over the past decade.
More recently, the focus for reperfusion timeliness has shifted from the “D2B” time to the broader measure 
of “contact-to-device” time following the 2017 European Society of Cardiology STEMI management guideline2. 
Contact-to-device time has advantages in capturing the various sub-components of reperfusion delay within 
the system of STEMI care. Yet, despite being a more comprehensive indicator of “system delay”, particularly in 
settings where prehospital system is better developed, contact-to-device time is less relevant in regions where 
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prehospital system remains immature3. Hence, D2B time being a measure of the in-hospital processes, remains 
highly relevant under these circumstances.
Over the past decade, health systems in the developed world have reported significant improvement in the 
timeliness of reperfusion therapy via pPCI based on the D2B time indicator4,5. However, more recent evaluation 
of the improvements in D2B time shows a lack of population effect4,6. Population effect is referred as the average 
differences in outcomes between the exposed and unexposed across all units in a population. The findings raised 
questions about the causal nature of the time-outcome relation at the population level 4,6,7. The argument also ele-
vated the fact that not all existing evidence are pointing at a significant effect that D2B delays has on ST-elevation 
myocardial infarction (STEMI) outcomes4,7. Recent review8 indicated that large proportion of the available evi-
dence lack adequate confounder consideration. Only 20% of the reported analyses have considered some aspects 
of the confounding domains. Importantly, merely one9 (out of the 35 studies reviewed) has considered at least 
some aspects of all the identified confounding domains. Common confounding domains that lack consideration 
in many of the previous reports include pre-hospital delays, day-time and institutional factors.
In addition, existing studies reported almost exclusively the effect of D2B delay on STEMI outcomes in relative 
term, based mainly on conventional regression method. The population-level effects of D2B delay on STEMI 
outcomes in absolute term remain largely unknown8. Relative estimates derived using regression adjustment, par-
ticularly the logistic and proportional hazard models, have important limitations. Firstly, they do not provide the 
magnitude of the effect size in absolute term, which is important to population-level decision making. Secondly, 
an adjusted relative effect via regression (e.g. odds ratio) can only be used to infer to the “average” subpopulation 
specific to the particular regression model. This subpopulation is often arbitrary and is difficult to relate to in 
real-life10,11. Generalizing this quantitative relationship to the population level can be misguiding12,13.
Hence, in this study, we considered (1) the covariates balancing propensity score (CBPS) method to consider 
the accessible, observed factors captured in the study database; (2) a distance-based instrumental variable (IV) 
analysis to further consider the unobserved confounders. These methods allowed us to address the concerns 
of the observed and unobserved factors potentially biasing the time-outcome relationship. Additionally, the 
population-average effects of D2B delay on STEMI outcomes were also examined and reported, which provide the 
information important to population health decision makers. We hypothesized that longer D2B delay is related 
to a higher population-level risk of adverse STEMI outcomes despite the additional confounding consideration.
Results
Study cohort and crude comparison. The MIG PCI registry included data for 5031 patients who under-
went primary PCI between January 2005, and March 2015. We excluded 688 patients who had D2B times in 
exceeds of 6 hours. 4343 patients (mean age was 63.2 years, with 78.2% males) fulfilled the study criteria. 1651 of 
them (38.0%) experienced a D2B delay of >90 minutes. Figure 1 depicts further details of the number of subjects 
included in the CBPS analysis and IV analysis.
The cohort median D2B time was 88.5 (SD = 51.4) minutes. Median D2B time was 58.8 minutes (SD = 19.2) 
in the <90 minutes stratum and 136.9 minutes (SD = 50.9) for the ≥90 minutes stratum. Table 1 shows a selection 
of the study cohort characteristics at baseline and stratified by D2B time. Overall, those who have experienced 
a longer D2B delay were found to be systematically differed from those with shorter D2B time. For instance, the 
longer D2B time subgroup were more likely to be older, of female sex, lower smoking prevalence, more likely to 
have a history of heart failure within the past 2 weeks, has higher pre-procedural TIMI flow and of higher baseline 
Killip class. Many of these factors are indicative of a higher risk of adverse outcomes. They also differed systemati-
cally by their angiographical characteristics. Weekend admission and off-hour presentation were related to longer 
D2B time. (See full details in Appendix A-5) Crude event rates for all study outcomes were higher for those with 
longer D2B delay (Table 2).
Effect estimates by CBPS analysis. Application of the CBPS model weights substantially improved the 
covariate balance between the comparator groups (Fig. 2 & Appendixs A-6 and A-7). All variables included in 
the CBPS model show no observable differences (all SMD < 0.1). The CBPS adjusted effect estimates for all study 
outcomes and their corresponding bootstrapped confidence interval are presented in Table 2. Overall, longer 
D2B delay, after CBPS adjustment, remained significantly associated with an increased risk of in-hospital and 
30-day mortality as well as in-hospital shock and MACE. Notably, the magnitude of the effect sizes has reduced in 
comparison to the crude rates. The effect estimates for in-hospital arrhythmia and 30-day MACE has marginally 
exceeded the pre-determined alpha (0.05) after CBPS weighting.
Effect estimates by IV analysis. 2543 patients remained for the IV analysis after the excluding those 
resided in areas of DD < 5 kilometers. (Fig. 1) Among them, 1234 (48.5%) patients had a DD of >5 km. The partial 
F statistics estimated in the first stage of the 2SLS was 36.6, which indicates that the IV performs well in predicting 
the exposure variable (i.e. D2B <90 and ≥90), hence can be considered an instrument with adequate strength. 
DD also appears to be a reasonably valid instrument as illustrated by an improved balance of the observed char-
acteristics in between the instrument strata (Fig. 2). Most observed factors achieved adequate balance with the 
SMD of <0.1. A particular concern of using DD as an instrument in this case was the potential of it being related 
to pre-hospital delay. If DD is related to pre-hospital delay, there is a possibility that DD may affect patient’s out-
come independently of D2B time, thereby rendering this instrument invalid (i.e. violation of the IV assumption). 
Our assessment however, indicates the absence of a statistical relationship between DD and pre-hospital delay 
(represented by the onset-to-door time (o2dt) variable in the dataset, see Appendix A-6). Other observed factors 
that have remained imbalance included the Index of Cardiac Accessibility and Remoteness, Index of Relative 
Socio-economic Disadvantage, Index of Economic Resources, Index of Education and Occupation, cohort year 
and systolic blood pressure (SBP) (See Appendixs A-6 and A-7). These imbalances indicate that the instrument is 
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likely to be systematically associated with patient’s socioeconomic status and treatment year. To account for these 
observed differences, we included these variables into the 2SLS model. For SBP, we observed that despite a mar-
ginally higher SMD for SBP between the two exposure subgroups, the absolute mean difference of SBP between 
the two subgroups was small (only 3.36 mmHg). This was judged to be clinically non-significant. Along with the 
generally well-balanced covariates of similar nature (e.g. Killip’s class) which represented adverse outcome risks, 
we believe that this small imbalance was likely non-systemic. Adjustment was therefore deemed unnecessary and 
not performed.
IV effect estimates (adjusted for patient socioeconomic and admission year differences) for longer D2B delay 
on the STEMI outcomes are presented in Table 2. All the effect estimates appear to be directionally consistent with 
that of CBPS. However, widened confidence intervals are seen across all the outcome examined. Statistical signif-
icance defined at α = 0.05 was not achieved for any of these endpoints. Note that relative effects were not reported 
for the IV analysis. This is because the conventional 2SLS approach of IV analysis used in this study allow only the 
derivation of the absolute (marginal) risk difference (and the corresponding 95% CI)14. Relative risk reporting in 
IV analysis requires a different modelling approach hence was not performed.
Discussion
Among those undergoing pPCI in Victoria, Australia during 2005 to 2015, we observed a trend indicating a con-
sistent link between longer D2B delay and higher risk of adverse STEMI outcomes despite the added confound-
ing consideration. This observation was based on a propensity score analysis implemented through the CBPS 
algorithm and an IV analysis that used patient-level “differential distance” as a pseudo-randomizer. Through 
the CBPS algorithm15, two highly comparable groups on all observed dimension were obtained. The IV analysis 
then further this agenda to consider the potential biases arising from the unobserved factors. These analyses were 
intended to consider the possibility of a confounded effect that D2B delay has on STEMI outcomes previously 
reported. It appears that D2B time exceeding 90 minutes is consistently associated with a higher risk of most study 
outcomes in the CBPS analysis. The effect estimates for all the study outcomes are still directionally consistent 
with that of the CBPS analysis when we further considered the IV approach, albeit a widened confidence interval 
that marginally covering the null.
This study also adds to the existing literature by reporting on the population average effect previously una-
vailable. To date, available literature lacks this important insight. Previous studies have expressed almost exclu-
sively the effect in relative terms. As relative effect measures often yield apparently larger effects size than their 
Figure 1. Derivation of the study cohort for propensity score analysis and instrumental variable analysis. 
D2B = Door-to-balloon, pPCI = Primary percutaneous coronary intervention, STEMI = ST-elevation 
myocardial infarction, CBPS = Covariates balancing propensity score, IV = instrumental variable, 
DD = Differential distance.
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absolute counterpart, healthcare managers and policy makers can be misguided if informed solely by the relative 
measures. Furthermore, previous D2B time-outcome studies estimated the relative effects mainly through the 
conventional use of logistic and Cox regression model. While these approaches offer a “conditional” effect esti-
mate familiar and meaningful in the clinical setting, particularly for clinician-patients communication, they are 
of limited relevance to policy makers and population health decision makers. These group of evidence users rely 
more on the population average effect (also known as the marginal effect). The population average effect measure, 
whether in absolute or relative term, represents the change in exposure averaged across the whole population 
without assuming complete knowledge of the risk model, similar to those offered by a randomized trial16. This 
contrasts with the conditional effect offered by multivariate logistic and Cox regression, which is relevant only to 
a specific and often arbitrary substratum of individuals within the target population11. In this study, we reported 
the population average effect in both relative and absolute term to fill this current evidence gap. Based on the 






>90 mins Std. 
DiffN = 4343 n = 2692 n = 1651
Age, mean (sd) 63.29 (12.81) 62.79 (12.47) 64.09 (13.31) 0.101
Male, n (%) 3398 (78.2) 2152 (79.9) 1246 (75.5) 0.108
Smoking history, n (%) 0.09
   Current 1545 (35.6) 988 (36.7) 557 (33.7)
   Prior 1205 (27.7) 751 (27.9) 454 (27.5)
   Never 1502 (34.6) 906 (33.7) 596 (36.1)
   Missing/Unknown 91 (2.1) 47 (1.7) 44 (2.7)
Congestive heart failure (within 2 
weeks), n (%) 259 (6.0) 130 (4.8) 129 (7.8) 0.133
   Missing 2 (0.0) 0 (0.0) 2 (0.1)
Pre-procedural TIMI flow, n (%) 0.193
   0 3053 (70.3) 1976 (73.4) 1077 (65.2)
   1–2 665 (15.3) 380 (14.1) 285 (17.3)
   3 620 (14.3) 335 (12.4) 285 (17.3)
   Missing 5 (0.1) 1 (0.0) 4 (0.2)
Killip class, n (%) 0.146
   1 3160 (72.8) 2014 (74.8) 1146 (69.4)
   2 463 (10.7) 272 (10.1) 191 (11.6)
   3 100 (2.3) 48 (1.8) 52 (3.1)
   4 352 (8.1) 197 (7.3) 155 (9.4)
   Not recorded 60 (1.4) 31 (1.2) 29 (1.8)
   Missing 208 (4.8) 130 (4.8) 78 (4.7)
Cardiogenic shock
(Pre-procedure), n (%) 465 (10.7) 248 (9.2) 217 (13.1) 0.125
Previous MI, n (%) 553 (12.7) 305 (11.3) 248 (15.0) 0.11
   Missing 9 (0.2) 5 (0.2) 4 (0.2)
Congestive heart failure, n (%) 73 (1.7) 30 (1.1) 43 (2.6) 0.111
   Missing 9 (0.2) 6 (0.2) 3 (0.2)
Right coronary lesion, n (%) 1794 (41.3) 1233 (45.8) 561 (34.0) 0.243
Circumflex lesion, n (%) 466 (10.7) 252 (9.4) 214 (13.0) 0.115
Obtuse marginal branch lesion, 
n (%) 223 (5.1) 106 (3.9) 117 (7.1) 0.138
Reference vessel 
diameter < = 2.5 mm, n (%) 837 (19.3) 430 (16.0) 407 (24.7) 0.217
Number of stents in procedure, 
n (%) 0.141
   1 280 (6.4) 144 (5.3) 136 (8.2)
   2 3161 (72.8) 2001 (74.3) 1160 (70.3)
   3 737 (17.0) 435 (16.2) 302 (18.3)
   4 or more 165 (3.8) 112 (4.2) 53 (3.2)
Weekend admission, n (%) 1222 (28.1) 664 (24.7) 558 (33.8) 0.202
Off-hour presentation, n (%) 2075 (47.8) 1120 (41.6) 955 (57.8) 0.333
Table 1. Baseline characteristics of the study cohort – overall and by D2B time experience. 
TIMI = Thrombolysis in Myocardial Infarction; MI = Myocardial infarction; sd = standard deviation, Std. 
Diff = standardized difference.
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Comparison by D2B time
D2B time
Relative Risk (95% CI) Risk Difference (95% CI)≤90 mins >90 mins
No. of patients n = 2692 n = 1651
Primary outcomes Unadjusted p-value Unadjusted p-value
   In-hospital mortality, n (%) 134 (5.0) 167 (10.1) 2.03 (1.63, 2.53) <0.001 5.14 (3.47, 6.81) <0.001
   30-Day mortality, n (%) 145 (5.4) 183 (11.1) 2.06 (1.67, 2.54) <0.001 5.70 (3.96, 7.44) <0.001
Secondary outcomes
   In-hospital arrhythmia, n (%) 488 (18.1) 367 (22.2) 1.23 (1.09, 1.38) <0.001 4.10 (1.62, 6.58) <0.001
   In-hospital shock, n (%) 188 (7.0) 188 (11.4) 1.63 (1.34, 1.98) <0.001 4.4 (2.59, 6.21) <0.001
   In-hospital MACE, n (%) 574 (21.3) 452 (27.4) 1.28 (1.15, 1.43) <0.001 6.05 (3.41, 8.70) <0.001
   30-Day MACE, n (%) 888 (33.0) 649 (39.3) 1.19 (1.10, 1.29) <0.001 6.32 (3.37, 9.27) <0.001
Primary outcomes CBPS adjusted CBPS adjusted
   In-hospital mortality — — 1.52 (1.15, 1.88) 0.001 2.81 (1.04, 4.58) 0.002
   30-Day mortality — — 1.58 (1.21, 1.95) <0.001 3.37 (1.49, 5.26) <0.001
Secondary outcomes
   In-hospital arrhythmia — — 1.13 (0.97, 1.29) 0.090 2.78 (−0.49, 6.02) 0.092
   In-hospital shock — — 1.25 (0.99, 1.51) 0.034 1.93 (0.05, 3.80) 0.044
   In-hospital MACE — — 1.15 (1.01, 1.28) 0.029 3.25 (0.23, 6.27) 0.034
   30-Day MACE — — 1.09 (0.98, 1.20) 0.080 3.22 (−0.26, 6.71) 0.069
Comparison by differential 
distance
Differential distance
<−5 km >5 km
No. of patients* n = 1309 n = 1234
Primary outcomes 2SLS IV adjusted
   In-hospital mortality, n (%) 77 (5.9) 96 (7.8) — — 20.7 (−2.6, 44.0) 0.081
   30-Day mortality, n (%) 83 (6.3) 104 (8.4) — — 22.6 (−1.7, 47.0) 0.068
Secondary outcomes
   In-hospital arrhythmia, n (%) 220 (16.8) 247 (20.0) — — 31.3 (−5.3, 67.9) 0.094
   In-hospital shock, n (%) 91 (7.0) 110 (8.9) — — 23.1 (−1.5, 47.7) 0.066
   In-hospital MACE, n (%) 266 (20.3) 297 (24.1) — — 34.5 (−4.6, 73.7) 0.084
   30-Day MACE, n (%) 415 (31.7) 437 (35.4) — — 37.4 (−7.0, 81.7) 0.099
Table 2. Crude and adjusted relative and absolute effect of D2B delay on STEMI outcomes. D2B = Door-
to-balloon, STEMI = ST-elevation myocardial infarction, MACE = Major adverse cardiac event, 
CBPS = Covariates balancing propensity score, 2SLS = two stage least square, IV = instrumental variable.
Figure 2. Balance of observed factors in between the comparison groups. SMD = Standardized mean 
difference, CBPS = Covariates balancing propensity score, IV = Instrumental variable.
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58.8 minutes across the whole study population) can potentially add 1.04–4.58 in-hospital deaths per 100 STEMI 
patients receiving pPCI. This suggest that one life might be lost by failure to optimizing D2B time in every 22 to 
96 STEMI patients receiving the procedure.
Study limitation. Despite the value and strength of this study discussed above, there are several limitations 
to consider. Firstly, the effect estimates captured via PS analysis and IV analysis are in fact conceptually differ-
ent. In the IV analysis, the local average treatment effect is estimated. The local average treatment effect refers 
to the effect of the exposure on the “compliers”. Compliers in our IV analysis represent those whose D2B time 
experience differed according to their relative distance to hospitals with longer or shorter D2B time. In the PS 
analysis, the treatment effect is obtained by averaging the differences of the outcome rates across the whole study 
cohort17,18. Only when the treatment effect is homogeneous across the study population, this difference will coin-
cide. Hence, readers should be aware that the effect estimates reported through these different analyses are likely 
non-identical.
Secondly, an IV analysis is limited by its underlying assumptions. The essential assumptions are that the 
instrument is: (1) associated with the treatment; (2) independent of all the confounding factors; and (3) inde-
pendent of the outcomes given the treatment and the confounders. These assumptions can only be supported 
indirectly but not be verified with certainty. We demonstrated the IV strength and assessed the covariates bal-
ances in between to IV subgroups. The balances of the observed factors achieved by the IV were not as optimal as 
that seen in the CBPS analysis. Adjustment was made to these observed imbalances to alleviate potential residual 
biases. Through these adjustment, the assumptions needed to establish a reasonably valid IV analysis likely stand. 
Moreover, it has been suggested that, as long as these assumption are reasonably valid (need not be perfectly 
valid), the resulting IV estimates are still comparatively less bias19.
Thirdly, we realized that there are two potential sources where the instrumental variable might be misclassi-
fied: (1) the utilization of the postcode centroid as a representation of the patient’s location at event onset (vs. the 
actual location of the patient): Patients’ residential postcode reflect the likely location or area where he/she might 
be at the time of the cardiac event onset. But this is certainly less desirable compare to using the actual onset 
location. Unfortunately, this detailed data is unavailable to us. The mechanism of this potential misclassification 
is likely random; hence a systemic bias is not likely. Nevertheless, the variance of the (instrumental) variable 
might be increased as a result of this additional random error. (2) the use of travel distance as a representation 
of the proximity to the nearest hospitals (instead of other potentially more accurate indicator, e.g. the actual 
required travel time at event onset): Similarly, we deducted that this mechanism of misclassification will likely 
cause non-systemic errors to the IV classification. The key concern of a larger variance for the IV is that the IV 
strength might be weakened as a result. Yet, our assessment has determined that, despite the increased variance, 
the IV remains sufficiently powerful in predicting the exposure variable.
Lastly, the observational nature of our study precludes causal conclusions despite the intention of addressing 
both the observed and unobserved factors. Particularly, our results might be explained by residual confounding 
if the instrument is related to other unobserved factors such as treatment and facility characteristics. Evidence 
from our IV analysis therefore cannot exclude the presence of unmeasured confounding between the D2B 
time-outcome association. Further analysis is required to assess this issue. However, as the centers included in the 
MIG dataset are largely similar in term of these dimensions, this concern should be considered minimal.
In conclusion, a consistent linkage between longer D2B delay and higher risk of adverse STEMI outcomes is 
supported at the population level. These linkages persisted despite adjusting for the observed and unobserved 
factors potential of confounding the relation. The population average effects reported in this study indicate that 
failure to optimize the D2B time in pPCI can have significant negative impact on STEMI population outcomes.
Methods
Data sources and the study cohort. We derived the study cohort from the Melbourne Interventional 
Group (MIG) PCI registry20, a collaborative multicenter registry of Australian public referral hospitals. Details 
of the MIG PCI registry has been previously described21–23. Briefly, the baseline demographics, clinical, angio-
graphic, and procedural characteristics of consecutive patients undergoing PCI are prospectively recorded using 
standardized definitions21,22. The study protocol was approved by the ethics committee in each participating hos-
pital with the use of “opt-out” consent. To “opt-out” means the participant can choose to have any or all of the 
information about them removed from the MIG registry when indicated. In-hospital outcomes and complica-
tions were recorded at the time of discharge. Cardiac research nurses conducted 30-day follow-ups by telephone, 
using a standardized questionnaire. All adverse events were verified by reviewing the patients’ medical records 
at the relevant hospitals. The Centre for Cardiovascular Research & Education in Therapeutics, a research body 
within the Department of Epidemiology and Preventive Medicine, Monash University coordinated the registry. 
An independent audit is routinely conducted at all enrolling sites by an investigator not affiliated with that insti-
tution. Data accuracy was 97%24.
We included adult patients (≥18 years) with STEMI admitted to one of the six participating hospitals in 
Victoria, Australia during 2005–2015. We excluded patients with D2B time of greater than 6 hours. This 
study was approved by the Monash University Human Research Ethics Committee (MUHREC Project num-
ber: CF15/4503-2015001952) who determined that this study satisfied section 5.1.22 of the Australia National 
Statement on Ethical Conduct in Human Research. The MIG registry steering committee permitted the conduct 
of this study after the MUHREC review exemption. Reporting of this study is in accordance to the Strengthening 
the Reporting of Observational studies in Epidemiology guideline. (See Appendix A-1).
Study context. There are 13 public hospitals and 18 private hospitals across all areas of Victoria, Australia. 
STEMI patients in Victoria have been predominantly treated in the public sector (~90% of all STEMI cases), with 
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close to 90% of the pPCI being performed in the public hospital system25. Emergency responses, pre-hospital 
cares and inter-hospital transfers of acute patients across the public and private system, including when a car-
diac condition is suspected, are delivered by Ambulance Victoria. A patient located in the metropolitan with 
a suspected STEMI will typically be taken to the nearest emergency department (of a public hospital) at the 
time of onset. The pre- and in-hospital processes & management of STEMI in Victoria for the public hospitals 
are standardized across regions of Victoria. Patients who are privately insured and located within the inner city 
may opt for a private facility for their STEMI care and be transferred accordingly. However, scenario as such are 
considered the minority. A geo-graphical illustration of the cardiac centers distribution in Victoria is provided in 
Appendix A-2. More general information on the Australian health system can be referred to here26.
The MIG registry dataset used in this study was derived from six public hospitals that provided specialist car-
diac services for adult patients20: The Alfred, Austin Hospital, University Hospital Geelong, The Royal Melbourne 
Hospital, Box Hill Hospital and Ballarat Health Services. These six public centers represented close to 40% of 
the overall primary PCI caseload within the Victoria state. Most of the PCI procedures performed in the private 
hospitals were elective cases. Slight differences have been observed in between the STEMI patients treated by 
the public cardiac centers and those treated in the private hospitals: STEMI patients in the private sector were 
observed to be slightly older (66.3 ± 12.1 private sector vs 62.7 ± 12.4 public sector), but otherwise had similar 
gender and risk profiles as those treated in the public centers25.
Exposures and outcome variables. The exposure variable under study was the patient-level D2B time. 
D2B time refers to the time from a patient’s arrival to a pPCI capable hospital to the first device use during pPCI. 
Examples of the first device used include, but are not limited to balloon, thrombectomy device, atherectomy 
device or stent. When the lesion failed to be crossed by the guidewire or device, the device time was taken as the 
time that the guide catheter was initially introduced. We examined the effect of D2B time has on STEMI out-
comes by considering D2B time as a dichotomized variable: ≤90 minutes vs. >90 minutes.
Primary outcomes assessed included in-hospital and 30-day mortality. In-hospital shock, arrhythmia and 
in-hospital and 30-day composite endpoints (major adverse cardiac event, MACE) were considered as secondary 
outcomes. Shock is referred if the patient suffered a new episode or acute recurrence of cardiogenic shock follow-
ing the PCI procedure. (See Appendix A-2). Arrhythmia refers to a new episode or acute recurrence of an atrial 
or ventricular arrhythmia requiring treatment or a new episode of high-level atrioventricular block. In-hospital 
MACE is defined as the presence of in-hospital shock, arrhythmia or death; 30-day MACE is defined as the pres-
ence of any of the following: in-hospital MACE, readmission and 30-day death.
Mortality data (30-day) were obtained by linkage to the Australian National Death Index23. The Australian 
National Death Index is a database that contains records of all deaths occurring in Australia since 1980. Successful 
matching of patients through this linkage process was achieved in 99.42% of patients in the MIG registry.
Other variables. We assessed the baseline characteristic of the whole study cohort and the differences in 
patient characteristics by D2B delay. Demographic variables included age, sex, and race at the time of the proce-
dure. The Socio-Economic Indexes for Areas27 developed by the Australian Bureau of Statistics and the Cardiac 
Accessibility and Remoteness Index for Australia28 were used to represent a patient’s socioeconomic status and 
health service accessibility based on their place of residence. We also assessed patients’ comorbidities, pre-hospital 
delay, day-time factors of STEMI onset and angiographic variables.
Analytic approaches. Covariate balancing propensity score analysis. Propensity score is the estimated 
probability of a study subject experiencing an exposure29. Weighting the subjects based on their propensity score 
create a pseudo-cohort with balance covariates in between the comparison groups29. In this study, we modelled 
the PS using the CBPS approach30. This approach allows the simultaneous maximization the resulting covariate 
balance as well as the prediction of treatment assignment, thereby avoiding an iteration between model fitting and 
balance checking. Covariate balance after CBPS weighting was evaluated by comparing the weighted covariates 
in between the exposure groups. The list of predictors included in the CBPS model is provided in Appendix A-5.
The adjusted risk of the study outcomes for each exposure group were calculated by weighting the outcomes 
using the CBPS weights. Comparison of the weighted risks in between the exposure groups were made; the pop-
ulation average relative risk and absolute risk differences were reported. The corresponding bootstrapped (200 
iterations) 95% confidence intervals were provided. The CBPS weights were re-estimated in each iteration of 
bootstrapping.
Instrumental variable analysis. An “instrument” is used in an IV analysis to achieve a natural randomization 
that minimizes the biases from both the measured and unmeasured confounders14,31,32. There are several common 
sources of IV for comparative studies in medicine. The potential sources of IV include: (variation of) physician 
treatment preference, exposure time, and natural genetic variants19. Distance has been another commonly con-
sidered variable that poses features of a suitable instrument, particularly in condition of emergent nature (like 
STEMI). This is because proximity of a patient to an emergency care provider (i.e. distance) generally enhances 
the likelihood of him/her being treated by the specific care provider. For less acute conditions, patients and 
providers will have more time to plan and decide where to be better treated. Hence proximity may have lesser 
influence on treatment selection/exposure. McClellan et al.’s study on cardiac catheterization effects on STEMI 
outcomes represents a classic example of a distance-based IV analysis under an emergent condition33. The IV 
used in McClellan’s study was the “differential distance” (DD) the patient lives from the nearest hospital that 
performs cardiac catheterization to the nearest hospital that does not perform cardiac catheterization. Because 
distance to a specialty care provider is often associated with socioeconomic characteristics, it is often necessary to 
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control for the socioeconomic characteristics in order for distance to potentially be independent of the unmeas-
ured confounders. Additionally, the possibility that distance might have a direct effect on outcomes (because the 
time taken to receive treatment may have the potential to affect outcomes) also will required explicit considera-
tion in order to ensure the high validity of the IV.
Our analysis took reference of McClellan et al.’s study and several other similar studies34,35. We used the DD 
as an instrument to achieve a pseudo-randomization objective as per above description. DD of a STEMI patient 
in this study is referred to as the additional distance one has to travel beyond his or her nearest hospital in order 
to reach another hospital with a shorter (median) D2B time (see Appendix A-3 for the conceptual illustration). 
A positive DD means that the patient is relatively farther away from a hospital with shorter D2B time; a negative 
DD means otherwise. Patients with STEMI who arrive at a hospital with shorter median D2B time are more likely 
to experience a timely reperfusion. Moreover, differential distance is unlikely to be related to patients’ outcome 
independently except through the better chance of experiencing a shorter D2B time given that the socioeconomic 
variables are adjusted.
We used the “geocode” function from the ggmap package25 of R to obtain the longitude and latitude of each 
patient’s location based on the postcode of their residential address. The geocode function operated by interfacing 
with the Google Geocoding API, which call for the longitude and latitude value of each input residential postcode 
area (the centroid of the postcode area) from the google map. A similar process was applied to obtaining the 
longitude and latitude data for each of the registry hospital. To derive the driving distances from each patient’s 
geocoded location to their two nearest hospitals, we used the “gmapsdistance” function. This function uses the 
Google Maps Distance Matrix API to compute the (driving) distance between two points on the globe.
After obtaining the distance data from the above process, differential distance was computed as per the 
description provided above. From there, we excluded those who resided in zip codes where the absolute DD was 
less than 5 kilometers to improve the instrumental strength. We then dichotomized the DD into two groups. DD 
>5 km refers to those whose residential location were comparatively farther away from a hospital with shorter 
median D2B time; DD <−5 km refers to the opposite.
Estimation of the effect of D2B time reduction using the differential distance as a randomizer were imple-
mented through a 2-stage least square (2SLS) model14,19. The strength of the instrument is assessed during the 
first stage by observing the F-statistic of the least square model. An F-statistic of greater than 10 is considered 
an adequately strong instrument19,36. The assumption that the instrument is unrelated to the study outcomes 
except through the exposure is assessed by comparing the observed differences in between the 2 differential dis-
tance groups11. A balance of observed covariates in between the two differential distance groups suggest that this 
assumption is reasonably valid. Robust standard errors were used. The absolute risk differences on the complier 
sub-population is reported. Reporting standards previously published were used19,36. (See Appendix A-4).
Missing data and imputation. To allow for the uncertainty arising from missing data, we used the multiple 
imputation technique37. The AMELIA II imputation package38 was used which implements a bootstrapping-based 
algorithm using the expectation–maximization and Bayesian hierarchical classification model. Five copies of the 
dataset with the missing values were replaced by imputed values. The CBPS analysis were executed to each of 
the imputed datasets. An overall estimate (with standard error) were obtained by applying the Rubin’s rules39. 
Imputed datasets were not used for the IV analysis as variables needed for the IV analysis contains no missing 
data.
All analyses were performed using R version 3.3.1 and evaluated at a 2-sided significance level of p < 0.05. 
sized differences (SMD) of covariates of ≤0.1 (i.e. one-tenth of a standard deviation apart) between the compar-
ison groups are considered negligible. The 2SLS models were implemented using the ivpack package40 and the 
CBPS package15 for CBPS analysis.
Data availability
The data that support the findings of this study are available from the Melbourne Interventional Group (MIG) 
PCI registry. But restrictions apply to the availability of these data, as this health information is considered 
sensitive information under the Privacy Act, hence they are not publicly available.
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